Background
Breast cancer remains one of the most common cancers worldwide. A large proportion of cases, about 70%, are hormone receptor-positive and ERBB2-negative, meaning the cancer cells grow in response to estrogen or progesterone but do not overexpress ERBB2, also known as HER2. For this subtype of advanced breast cancer, endocrine therapy is the foundation of treatment. Aromatase inhibitors such as letrozole and anastrozole are commonly used to reduce estrogen production and slow tumor growth.
In recent years, combining endocrine therapy with a cyclin-dependent kinase 4 and 6 inhibitor has become an important strategy because it can delay disease progression more effectively than endocrine therapy alone. Fovinaciclib is an oral CDK4/6 inhibitor developed to enhance this approach. This phase 3 trial was designed to determine whether adding fovinaciclib to a first-line aromatase inhibitor could improve outcomes for patients with hormone receptor-positive, ERBB2-negative advanced breast cancer.
Study Design
This was a double-blind, randomized, placebo-controlled phase 3 clinical trial conducted at 63 centers in China. Patients were enrolled between March 2, 2022, and June 28, 2023. Eligible participants were adult women with advanced breast cancer that was hormone receptor-positive and ERBB2-negative, and who had not received prior systemic therapy for advanced disease.
A total of 417 women were randomized in a 1:1 ratio. One group received fovinaciclib plus an aromatase inhibitor, while the control group received placebo plus an aromatase inhibitor. The aromatase inhibitor was either letrozole 2.5 mg or anastrozole 1 mg, taken orally once daily. Fovinaciclib was given at 200 mg orally once daily on days 1 through 21 of each 28-day cycle, while placebo followed the same schedule. Premenopausal and perimenopausal patients also received goserelin 3.6 mg by subcutaneous injection on day 1 to suppress ovarian estrogen production.
The main measure of effectiveness was progression-free survival, or PFS, assessed by blinded independent central review. PFS refers to the length of time before the cancer grows or spreads, or before the patient dies from any cause. Secondary endpoints included additional efficacy outcomes and safety. Overall survival and quality of life were exploratory endpoints.
Key Results
At the time of the prespecified interim analysis, the median follow-up was 16.6 months. The median age of participants was 57 years, with ages ranging from 32 to 84 years. Of the 417 women, 208 were assigned to fovinaciclib and 209 to placebo.
The trial showed a clear benefit for fovinaciclib. Median progression-free survival was not yet reached in the fovinaciclib group, compared with 20.2 months in the placebo group. The hazard ratio was 0.55, indicating a 45% reduction in the risk of progression or death, and the result was statistically significant. These findings were confirmed by blinded independent central review, strengthening confidence in the benefit.
The treatment effect was generally consistent across most patient subgroups, suggesting that the benefit was seen broadly rather than being limited to a narrow set of participants. Fovinaciclib also performed better on other secondary efficacy measures, supporting the overall anti-cancer activity of the combination.
Overall survival data were still immature at the time of analysis. Only 40 death events had occurred, representing 9.6% of the study population, so it was too early to determine whether the improvement in progression-free survival would translate into longer overall survival. Longer follow-up will be important for that question.
Safety Findings
The safety profile of fovinaciclib was manageable. The most common treatment-emergent adverse events were hematologic toxic effects, meaning changes in blood cells such as neutropenia, anemia, or thrombocytopenia. These effects are commonly seen with CDK4/6 inhibitors and are generally monitored through regular blood tests.
Importantly, no treatment-emergent adverse events led to serious complications or required permanent discontinuation of the study drug. The rate of discontinuation due to adverse events was very low and identical in both groups, at 1.4%: 3 of 208 patients in the fovinaciclib group and 3 of 209 in the placebo group. This suggests that adding fovinaciclib did not meaningfully increase the likelihood of stopping treatment.
From a practical standpoint, these findings are reassuring because first-line therapy for advanced breast cancer often needs to be continued for a prolonged period. Treatments that are effective but difficult to tolerate can undermine long-term disease control. In this study, efficacy improved without a major penalty in safety.
Quality of Life
Quality of life is a critical outcome in advanced cancer treatment. Extending time without progression is valuable, but it should not come at the cost of major day-to-day symptom burden. In this trial, longitudinal assessments using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 showed similar results between the two treatment arms.
This means that global health status, functional domains, and symptom domains were not meaningfully worse in patients receiving fovinaciclib. For patients and clinicians, that is an important finding: the addition of fovinaciclib appears to improve disease control while preserving overall well-being.
Clinical Meaning
The results of this trial support fovinaciclib plus aromatase inhibitor therapy as a strong first-line option for patients with hormone receptor-positive, ERBB2-negative advanced breast cancer. In this setting, the main treatment goal is often to control the disease for as long as possible while maintaining quality of life and delaying the need for chemotherapy.
The observed improvement in progression-free survival is clinically meaningful because it suggests longer disease control and a delay in progression-related symptoms and treatment changes. For many patients, this can translate into more time with stable disease, fewer urgent treatment switches, and potentially a better overall treatment experience.
As with all phase 3 trials, interpretation should consider the follow-up duration. Overall survival remains the most definitive endpoint, but it often requires longer observation, especially when effective subsequent therapies are available after progression. Even so, progression-free survival is a highly relevant outcome in advanced hormone receptor-positive breast cancer and is widely used to guide practice.
How This Fits Into Current Care
Hormone receptor-positive, ERBB2-negative advanced breast cancer is commonly treated with endocrine therapy, often combined with targeted agents. CDK4/6 inhibitors are among the most established targeted options in this setting. Fovinaciclib appears to join this therapeutic class with meaningful activity when used with an aromatase inhibitor.
The study also highlights several practical aspects of care. Premenopausal and perimenopausal patients need ovarian suppression with goserelin so that endocrine therapy works effectively. Regular monitoring of blood counts is important because hematologic side effects are common. In routine practice, clinicians would also monitor for fatigue, gastrointestinal symptoms, and any signs of infection or other complications.
If additional studies confirm these findings across broader populations and longer follow-up periods, fovinaciclib could become an important component of first-line management for this breast cancer subtype. Future research may also help clarify which patients benefit most, how it compares with other CDK4/6 inhibitors, and whether specific biomarkers can guide treatment selection.
Limitations
There are a few limitations to keep in mind. First, the trial population was enrolled entirely in China, so results may need confirmation in more diverse global populations. Second, the overall survival analysis was not mature, so the effect on survival beyond progression-free survival is still unknown. Third, as with many targeted therapy trials, longer-term safety and real-world tolerability will be important to evaluate after broader use.
Despite these limitations, the trial was carefully designed, double-blind, and randomized, which makes the findings robust. The consistency of the efficacy signal, combined with manageable safety and stable quality-of-life results, supports the strength of the evidence.
Conclusion
In this randomized phase 3 trial, adding fovinaciclib to first-line aromatase inhibitor therapy significantly improved progression-free survival in women with hormone receptor-positive, ERBB2-negative advanced breast cancer. The benefit was seen across most subgroups, safety was manageable, discontinuation rates were low, and quality of life remained similar between groups.
These results suggest that fovinaciclib may offer an effective and well-tolerated new treatment option in the first-line setting for this common breast cancer subtype. Continued follow-up will be important to determine the impact on overall survival and to define the drug’s place in future treatment strategies.
